SCHEMBL21063354

SCHEMBL21063354

OCC(Cc1ccccc1)Nc1nc(Cl)nc2c(F)cccc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ CYP2D6 P10635 1/20 0.47
▸ ADORA1 P30542 3/20 0.46
▸ KCNH2 Q12809 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ AURKA O14965 3/20 0.40
▸ RPS6KB1 P23443 3/20 0.40
▸ ADORA2A P29274 2/20 0.39
▸ APP P05067 2/20 0.39
▸ PDE5A O76074 1/20 0.39
▸ CDK1 P06493 2/20 0.37
▸ CDK5 Q00535 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12165831 0.84 MAPT (0.64) KMT2AKDM4EMEN1MAPTADORA1
SCHEMBL8592661 0.75 ADORA1 (0.49) KMT2AKDM4EMEN1MAPTCYP2D6
SCHEMBL8592666 0.75 ADORA1 (0.49) KMT2AKDM4EMEN1MAPTCYP2D6
SCHEMBL8596568 0.75 ADORA1 (0.49) KMT2AKDM4EMEN1MAPTCYP2D6
SCHEMBL8907091 0.74 APP (0.55) KMT2AKDM4EMEN1MAPTKCNH2
SCHEMBL14670527 0.74 KDM4E (0.50) KMT2AKDM4EMEN1MAPTADORA1
SCHEMBL12165799 0.70 KDM4E (0.59) KMT2AKDM4EMEN1MAPTADORA1
SCHEMBL30486964 0.70 MAPT (0.44) KMT2AKDM4EMEN1MAPTADORA1
SCHEMBL21325639 0.69 CYP2D6 (0.85) CYP2D6ADORA1KCNH2
SCHEMBL13975907 0.69 CYP2D6 (0.85) CYP2D6ADORA1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3723754-B1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2026-05-13 — — EP disclosed
US-11498923-B2 Substituted imidazo[1,2-c]quinazolines as A2A antagonists MERCK SHARP & DOHME LLC (US) 2022-11-15 — — US disclosed
US-11498923-B2 Substituted imidazo[1,2-c]quinazolines as A2A antagonists MERCK SHARP & DOHME LLC (US) 2022-11-15 — — US disclosed
US-20210053973-A1 IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2021-02-25 — — US disclosed
US-20210053973-A1 IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2021-02-25 — — US disclosed
EP-3723754-A1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2020-10-21 — — EP disclosed
WO-2019118313-A1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2019-06-20 — — WO disclosed
WO-2019118313-A1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2019-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11498923-B2 Substituted imidazo[1,2-c]quinazolines as A2A antagonists ADORA2A, ADORA3, ADORA1 KMT2A 1005/4885KDM4E 3642/4885MEN1 2448/4885
US-20210053973-A1 IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES ADORA2A, ADORA3, ADORA1 KMT2A 997/4885KDM4E 3509/4885MEN1 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback